$4.2 Billion is the total value of Cormorant Asset Management, LP's 105 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 19.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TPTX | Sell | TURNING POINT THERAPEUTICS I | $291,501,000 | +36.6% | 2,392,297 | -2.0% | 6.94% | -15.4% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $98,780,000 | +7.5% | 2,495,066 | -5.5% | 2.35% | -33.5% |
| STOK | Sell | STOKE THERAPEUTICS INC | $89,043,000 | +72.9% | 1,437,807 | -6.5% | 2.12% | +7.0% |
| ALXO | Sell | ALX ONCOLOGY HLDGS INC | $76,009,000 | +111.4% | 881,770 | -9.3% | 1.81% | +30.8% |
| CCXI | Sell | CHEMOCENTRYX INC | $74,304,000 | -3.1% | 1,200,000 | -14.3% | 1.77% | -40.1% |
| IMVT | Sell | IMMUNOVANT INC | $72,193,000 | +25.3% | 1,562,952 | -4.6% | 1.72% | -22.5% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $62,895,000 | -9.6% | 2,464,547 | -2.0% | 1.50% | -44.0% |
| OMER | Sell | OMEROS CORP | $57,140,000 | +13.1% | 4,000,000 | -20.0% | 1.36% | -30.0% |
| XLRN | Sell | ACCELERON PHARMA INC | $54,374,000 | -3.4% | 425,000 | -15.0% | 1.29% | -40.2% |
| VIE | Sell | VIELA BIO INC | $51,408,000 | +15.5% | 1,429,200 | -9.8% | 1.22% | -28.5% |
| MYOV | Sell | MYOVANT SCIENCES LTD | $46,954,000 | +56.5% | 1,700,000 | -20.4% | 1.12% | -3.1% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $36,427,000 | +12.1% | 425,000 | -15.0% | 0.87% | -30.6% |
| TWST | Sell | TWIST BIOSCIENCE CORP | $31,790,000 | -16.3% | 225,000 | -55.0% | 0.76% | -48.2% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $30,713,000 | -54.1% | 4,500,000 | -25.0% | 0.73% | -71.6% |
| CRSP | Sell | CRISPR THERAPEUTICS AGnamen akt | $30,622,000 | +22.0% | 200,000 | -33.3% | 0.73% | -24.5% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $25,234,000 | -1.0% | 225,000 | -18.2% | 0.60% | -38.7% |
| CABA | Sell | CABALETTA BIO INC | $23,767,000 | +6.1% | 1,904,424 | -7.9% | 0.57% | -34.3% |
| BNTX | Sell | BIONTECH SEsponsored ads | $22,418,000 | +0.0% | 275,000 | -15.4% | 0.53% | -38.2% |
| AGEN | Sell | AGENUS INC | $22,260,000 | -34.5% | 7,000,000 | -17.6% | 0.53% | -59.4% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $19,158,000 | -27.6% | 742,549 | -13.6% | 0.46% | -55.2% |
| INSP | Sell | INSPIRE MED SYS INC | $18,809,000 | +21.5% | 100,000 | -16.7% | 0.45% | -24.7% |
| ALBO | Sell | ALBIREO PHARMA INC | $18,755,000 | -19.7% | 500,000 | -28.6% | 0.45% | -50.3% |
| OTIC | Sell | OTONOMY INC | $16,822,000 | +28.1% | 2,600,000 | -19.8% | 0.40% | -20.8% |
| ASND | Sell | ASCENDIS PHARMA A/Ssponsored adr | $16,678,000 | -13.5% | 100,000 | -20.0% | 0.40% | -46.5% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $16,294,000 | -8.5% | 200,000 | -20.0% | 0.39% | -43.4% |
| TCRR | Sell | TCR2 THERAPEUTICS INC | $15,465,000 | +26.8% | 500,000 | -16.7% | 0.37% | -21.5% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $11,934,000 | -0.0% | 70,000 | -17.6% | 0.28% | -38.1% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $11,414,000 | -11.0% | 200,000 | -20.0% | 0.27% | -44.8% |
| RPTX | Sell | REPARE THERAPEUTICS INC | $10,290,000 | -4.1% | 300,000 | -13.9% | 0.24% | -40.5% |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $10,146,000 | +17.5% | 300,000 | -14.3% | 0.24% | -27.4% |
| INSM | Sell | INSMED INC | $9,987,000 | -11.2% | 300,000 | -14.3% | 0.24% | -45.0% |
| AKUS | Sell | AKOUOS INC | $9,915,000 | -11.5% | 499,990 | -0.0% | 0.24% | -45.2% |
| TBPH | Sell | THERAVANCE BIOPHARMA INC | $9,773,000 | +1.7% | 550,000 | -15.4% | 0.23% | -37.0% |
| QURE | Sell | UNIQURE NV | $9,032,000 | -24.5% | 250,000 | -23.1% | 0.22% | -53.3% |
| ARGX | Sell | ARGENX SEsponsored adr | $8,823,000 | -16.0% | 30,000 | -25.0% | 0.21% | -48.0% |
| TARA | Sell | PROTARA THERAPEUTICS INC | $8,474,000 | +11.9% | 350,000 | -22.2% | 0.20% | -30.6% |
| QTNT | Sell | QUOTIENT LTD | $7,815,000 | -24.0% | 1,500,000 | -25.0% | 0.19% | -52.9% |
| ALLK | Sell | ALLAKOS INC | $7,000,000 | +14.6% | 50,000 | -33.3% | 0.17% | -28.9% |
| MORF | Sell | MORPHIC HLDG INC | $6,710,000 | -1.8% | 200,000 | -20.0% | 0.16% | -39.2% |
| MRUS | Sell | MERUS N V | $6,136,000 | +19.1% | 350,000 | -18.5% | 0.15% | -26.3% |
| GTH | Sell | GENETRON HLDGS LTDads | $5,600,000 | -6.2% | 400,000 | -20.0% | 0.13% | -42.2% |
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $4,916,000 | +34.4% | 400,000 | -11.0% | 0.12% | -17.0% |
| KDMN | Sell | KADMON HLDGS INC | $3,528,000 | -10.0% | 850,000 | -15.0% | 0.08% | -44.4% |
| TCDA | Sell | TRICIDA INC | $3,017,000 | -54.3% | 427,975 | -41.2% | 0.07% | -71.7% |
| CRDF | Sell | CARDIFF ONCOLOGY INC | $2,699,000 | +8.7% | 150,000 | -14.3% | 0.06% | -32.6% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $1,537,000 | -31.5% | 20,000 | -33.3% | 0.04% | -57.0% |
| FATE | Sell | FATE THERAPEUTICS INC | $909,000 | +51.5% | 10,000 | -33.3% | 0.02% | -4.3% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $680,000 | -18.1% | 40,000 | -20.0% | 0.02% | -50.0% |
| NERV | Sell | MINERVA NEUROSCIENCES INC | $468,000 | -38.3% | 200,000 | -16.3% | 0.01% | -62.1% |
| OTLKW | Exit | OUTLOOK THERAPEUTICS INC*w exp 02/18/202 | $0 | – | -416,666 | -100.0% | -0.00% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -300,000 | -100.0% | -0.05% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -931,800 | -100.0% | -0.17% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -470,897 | -100.0% | -0.19% | – |
| SRNE | Exit | SORRENTO THERAPEUTICS INCcall | $0 | – | -500,000 | -100.0% | -0.21% | – |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -1,000,000 | -100.0% | -0.23% | – |
| CCXI | Exit | CHEMOCENTRYX INCcall | $0 | – | -250,000 | -100.0% | -0.53% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -130,000 | -100.0% | -0.71% | – |
| ARCT | Exit | ARCTURUS THERAPEUTICS HLDGS | $0 | – | -700,000 | -100.0% | -1.16% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -2,500,000 | -100.0% | -1.37% | – | |
| EIDX | Exit | EIDOS THERAPEUTICS INC | $0 | – | -993,185 | -100.0% | -1.93% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -450,000 | -100.0% | -2.36% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.